Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Rituximab Subcutaneous Formulation (SC-R) Is Safe, Effective and Cost-Saving in Patients Suffering from Autoimmune Hemolytic Anemia (AIHA)

Francesco Iuliano, MD, Eleonora Iuliano, MD, Alessia Perricelli, MD, Angelo Pomillo, MD, Maria Luci, MD, Maria Aquila Santoro, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2016) 128 (22): 1269.

https://doi.org/10.1182/blood.V128.22.1269.1269

Published: 2016

Journal Articles

Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT)

Francesco Iuliano, MD, Eleonora Iuliano, MD, Alessia Perricelli, MD, Maria Aquila Santoro, MD, Angelo Pomillo, MD, Maria Luci, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2016) 128 (22): 4926.

https://doi.org/10.1182/blood.V128.22.4926.4926

Published: 2016

Journal Articles

Effectiveness and Safety of Low Dose Eltrombopag Twice Weekly in ITP Patients That Achieved CR after 50mg Daily Standard Dose

Francesco Iuliano, MD, Eleonora Iuliano, MD, Alessia Perricelli, MD, Angelo Pomillo, MD, Maria Luci, MD, Elisabetta Abruzzese

Blood (2014) 124 (21): 2788.

https://doi.org/10.1182/blood.V124.21.2788.2788

Published: 2014

Journal Articles

Subcutaneous Immunoglobulin (SCIG) in Responders to Intravenous Therapy with Chronic Immune Thrombocytopenia (ITP)

Francesco Iuliano, MD, Eleonora Iuliano, MD, Maria Luci, MD, Alessia Perricelli, MD, Angelo Pomillo, MD, Elisabetta Abruzzese

Blood (2014) 124 (21): 5012.

https://doi.org/10.1182/blood.V124.21.5012.5012

Published: 2014

Journal Articles

Assisted Administration Of Subcutaneous 5-Azacytidine to The Patient's Home. Significant Reduction Of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together With a Total Adhesion To The Treatment Schedule and Same Safety

Francesco Iuliano, MD, Eleonora Iuliano, MD, Alessia Perricelli, MD, Angelo Pomillo, MD, Maria Luci, MD, Gianluca Cervo

Blood (2013) 122 (21): 5587.

https://doi.org/10.1182/blood.V122.21.5587.5587

Published: 2013

Journal Articles

Platelet Kinetic Study (PKS) May Early Identify a Subset of Patients with Immune Thrombocytopenia (ITP) Probably Cured by Romiplostim. Two Years Follow-up

Francesco Iuliano, MD, Alessia Perricelli, MD, Eleonora Iuliano, MD, Stefania Infusino, PhD, Angelo Pomillo, MD, Maria Luci, MD, Filippo Barbano, MD

Blood (2012) 120 (21): 1099.

https://doi.org/10.1182/blood.V120.21.1099.1099

Published: 2012

NARROW

Rituximab Subcutaneous Formulation (SC-R) Is Safe, Effective and Cost-Saving in Patients Suffering from Autoimmune Hemolytic Anemia (AIHA)

Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT)

Effectiveness and Safety of Low Dose Eltrombopag Twice Weekly in ITP Patients That Achieved CR after 50mg Daily Standard Dose

Subcutaneous Immunoglobulin (SCIG) in Responders to Intravenous Therapy with Chronic Immune Thrombocytopenia (ITP)

Assisted Administration Of Subcutaneous 5-Azacytidine to The Patient's Home. Significant Reduction Of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together With a Total Adhesion To The Treatment Schedule and Same Safety

Platelet Kinetic Study (PKS) May Early Identify a Subset of Patients with Immune Thrombocytopenia (ITP) Probably Cured by Romiplostim. Two Years Follow-up

Email alerts

ASH Publications

American Society of Hematology

Rituximab Subcutaneous Formulation (SC-R) Is Safe, Effective and Cost-Saving in Patients Suffering from Autoimmune Hemolytic Anemia (AIHA)

Low Doses of Eltrombopag Are Safe and Effective in the Prophylaxis of the Chemotherapy-Induced Thrombocytopenia (CIT)

Effectiveness and Safety of Low Dose Eltrombopag Twice Weekly in ITP Patients That Achieved CR after 50mg Daily Standard Dose

Subcutaneous Immunoglobulin (SCIG) in Responders to Intravenous Therapy with Chronic Immune Thrombocytopenia (ITP)

Assisted Administration Of Subcutaneous 5-Azacytidine to The Patient's Home. Significant Reduction Of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together With a Total Adhesion To The Treatment Schedule and Same Safety

Platelet Kinetic Study (PKS) May Early Identify a Subset of Patients with Immune Thrombocytopenia (ITP) Probably Cured by Romiplostim. Two Years Follow-up

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only